Data from EMC - Curated by Toby Galbraith - Last updated 19 May 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to Factor VIII.

OBIZUR is indicated in adults.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure

More information

Category Value
Agency product number EMEA/H/C/002792
Orphan designation No
Date First Approved 11-11-2015
Type POM
Marketing authorisation holder Baxalta Innovations GmbH
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions

Related Content